Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Dianthus Therapeutics Inc DNTH

Healthcare Biotechnology
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the... see more

Current News (NDAQ:DNTH)

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 7 days ago

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

GlobeNewswire December 23, 2025

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 24, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

GlobeNewswire November 5, 2025

Dianthus Therapeutics to Participate in Four Investor Conferences During November

GlobeNewswire November 4, 2025

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

GlobeNewswire October 29, 2025

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

GlobeNewswire October 16, 2025

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

GlobeNewswire October 2, 2025

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 11, 2025
View More News ››

Opinion & Analysis (NDAQ:DNTH)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DNTH)

Be the first to post on this bullboard.

EnviroGold Global Limited.

EnviroGold Global Limited.

EnviroGold Global Limited is a Canadian headquartered clean technology company with a global vision and a strategic focus ...
View More »

Podcasts